Radiation Therapy in Breast Cancer

Radiation therapy is a key part of breast cancer treatment for many patients. It is especially common after breast-conserving surgery and may also be recommended after mastectomy in selected higher-risk situations. The purpose is usually to reduce the risk of local or regional recurrence and, in appropriate settings, contribute to improved long-term outcomes. ^[1][2][3]

What is the main aim of radiotherapy in breast cancer?

After surgery, microscopic cancer cells can remain in the breast, chest wall, or regional nodes even when imaging and examination look reassuring. Radiotherapy is used to lower the chance that these cells will later cause recurrence. In breast-conserving treatment, the combination of surgery plus radiotherapy is a standard pathway for many patients because preserving the breast safely depends not only on removing the visible tumour but also on controlling residual microscopic disease. ^[1][2][4]

Which patients are more commonly advised to receive it?

Radiotherapy is commonly recommended after lumpectomy. After mastectomy, it may be advised depending on tumour size, nodal involvement, margin status, biologic risk, and other pathological features. Some patients may receive breast-only treatment, while others also require regional nodal irradiation. The decision is individual and depends on recurrence risk, anatomy, age, and the broader treatment plan. ^[1][2][5]

How are planning and treatment delivery performed?

Treatment planning involves simulation imaging, target contouring, and efforts to protect organs such as the heart and lungs. Positioning matters. For left-sided cancers in particular, heart-sparing techniques such as deep-inspiration breath hold may be used in appropriate patients to reduce cardiac exposure. This is one reason breast radiotherapy planning is not a simple routine step but a carefully engineered part of treatment. ^[1][2][6]

What side effects are most common?

Common side effects include fatigue, skin redness or darkening, breast or chest wall tenderness, swelling, and temporary discomfort. Some patients notice firmness, contour change, or persistent sensitivity later. Risk and intensity depend on the treated field, dose, individual skin response, prior surgery, and whether systemic therapy has also been given. ^[1][2][3]

How does radiotherapy affect survival and recurrence risk?

In appropriate settings, breast radiotherapy reduces local recurrence and contributes to improved long-term outcomes. That benefit is why the recommendation remains strong in many standard pathways after breast-conserving surgery and in selected higher-risk post-mastectomy cases. The conversation should focus not only on “Will it make me tired?” but also on how much recurrence reduction it is expected to provide in that specific case. ^[1][2][4]

What matters in long-term follow-up?

Long-term follow-up includes surveillance for recurrence, assessment of late skin and soft-tissue effects, shoulder mobility, lymphoedema risk when nodes are treated, and cardiopulmonary considerations where relevant. Radiotherapy does not end when the last session is over; its effects must still be interpreted over time. ^[1][2][6]

How is heart protection achieved in left-breast tumours?

Modern planning aims to minimise cardiac dose through careful positioning and techniques such as deep-inspiration breath hold when appropriate. Patients should know that heart protection is an active part of planning, not an afterthought. ^[1][2][6]

Why is follow-up needed for lymphoedema and shoulder movement?

When axillary or regional nodal treatment is involved—especially in combination with surgery—there may be increased risk of swelling, stiffness, and functional limitation. Early rehabilitation and awareness can improve long-term comfort and function. ^[1][2][5]

How is sequencing with chemotherapy and hormone therapy determined?

Radiotherapy timing depends on surgery, wound healing, chemotherapy plans, endocrine therapy, and overall treatment strategy. The sequence is individualised so that each modality is delivered at the most appropriate time. ^[1][2][4]